Newron Pharmaceuticals S.p.A.
NP5
Rank in Stocks
#17655
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Share Price
$10.77
Last synced: 2026-10-20
Market Cap
$220.23M
Change (1 day)
1.34%
Change (1 year)
-40.75%
Country
IT
Trade Newron Pharmaceuticals S.p.A. (NP5)
Category
Healthcare
Stock split history for Newron Pharmaceuticals S.p.A. (NP5)
Newron Pharmaceuticals S.p.A. stock (symbol: NP5) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 21, 2026.
One NP5 share bought prior to Oct 21, 2026 would equal to 0 NP5 shares today.
The most recent stock split occurred on Oct 21, 2026.
One NP5 share bought prior to Oct 21, 2026 would equal to 0 NP5 shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
